title: Return to work after acute ST-segment elevation myocardial infarction in the modern era of reperfusion by direct percutaneous coronary intervention.
abstract: BACKGROUND
  Previous studies have evaluated return to work after acute ST-segment elevation myocardial infarction (STEMI) treated medically, after bypass surgery or after percutaneous coronary intervention (PCI) for stable coronary artery disease. However, there are few data regarding return to work after acute STEMI treated by direct PCI.
  
  
  OBJECTIVE
  To analyse the factors influencing return to work after STEMI treated by direct PCI.
  
  
  METHODS
  Two hundred consecutive patients who underwent direct PCI for acute STEMI and who were employed at the time of their STEMI were studied. Stents were used in 94% of patients and glycoprotein IIb/IIIa inhibitors in 77%.
  
  
  RESULTS
  Among the 200 patients, 152 (76%) patients returned to work and 48 (24%) did not. Patients who did not return to work did not differ from those who returned to work in terms of time from onset of chest pain to PCI, STEMI location, left ventricular function, extent of vessel disease, PCI technique and success, completeness of revascularization, duration of hospital stay, intrahospital complications and performance of cardiac rehabilitation. Multivariable analysis showed that older age, daytime onset of chest pain, manual labour, rapid call-out of the emergency medical team, unmarried status and a limited number of risk factors were independent predictors of non-return to work.
  
  
  CONCLUSIONS
  Age, sociopsychological and occupational factors appear to be the strongest predictors of return to work after STEMI treated by direct PCI. Clinical and procedural factors as well as cardiac rehabilitation appear to have no impact on return to work in this subset of patients.
authors.affiliation: hôpital Nord, CHU de Saint-Etienne, France. isaaz@univ-st-etienne.fr
authors.forename: Karl
authors.initials: K
authors.lastname: Isaaz
authors.forename: Maud
authors.initials: M
authors.lastname: Coudrot
authors.forename: Mohamed H
authors.initials: MH
authors.lastname: Sabry
authors.forename: Alexis
authors.initials: A
authors.lastname: Cerisier
authors.forename: Michel
authors.initials: M
authors.lastname: Lamaud
authors.forename: Christophe
authors.initials: C
authors.lastname: Robin
authors.forename: Laure
authors.initials: L
authors.lastname: Richard
authors.forename: Antoine
authors.initials: A
authors.lastname: Da Costa
authors.forename: Hazem
authors.initials: H
authors.lastname: Khamis
authors.forename: Ahmed
authors.initials: A
authors.lastname: Abd-Alaziz
authors.forename: Claude
authors.initials: C
authors.lastname: Gerenton
mesh_terms: D000328:Adult; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation; D016009:Chi-Square Distribution; D004651:Employment; D005260:Female; D005602:France; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000534:rehabilitation / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D018582:Sick Leave; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex